OPEN ACCESS Freely available online

ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability

Opinion Article

Scaled Average Bioequivalency and Advancements in Generic Drug Development

Xinh Jon*

Department of Chemistry, University of Sydney, Sydney, Australia

DESCRIPTION

Bioequivalence is fundamentally about ensuring that two drugs, typically a generic and a brand-name drug, have comparable bioavailability, meaning they reach the bloodstream at similar rates and extents. This is important because it ensures that patients can expect the same therapeutic effects and safety profiles from the generic drug as they would from the brand-name drug. Traditionally, ABE has been the gold standard, where bioequivalence is assessed based on the comparison of pharmacokinetic parameters such as the Area Under the Curve (AUC) and the maximum concentration (Cmax) of the drug in the bloodstream. ABE works well for many drugs, but it falls short when dealing with highly variable drugs, which exhibit significant within-subject variability. These are drugs where the variability in pharmacokinetic parameters among different subjects or even the same subject at different times can be quite high. This inherent variability can make it challenging to demonstrate bioequivalence using traditional methods, potentially leading to the rejection of generic drugs that are, in fact, bioequivalent.

Highly variable drugs present a unique challenge. The natural pharmacokinetic variability can obscure the true performance of the generic drug, making it appear less consistent in comparison to the reference drug. This can result in unnecessary clinical trials, increased costs, and delays in bringing affordable generics to market. Recognizing this, regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have endorsed Scaled Average Bioequivalence (SABE) as a more appropriate method for assessing bioequivalence in such cases. SABE adjusts the bioequivalence criteria based on the within-subject variability of the reference drug. This scaling approach provides a more flexible and scientifically sound method for evaluating highly variable drugs. It ensures that the bioequivalence assessment is sensitive to the intrinsic variability of the drug, thereby preventing the rejection of generic drugs that would otherwise meet the therapeutic equivalence requirements.

SABE lowers the barriers for the approval of generic drugs, especially those with high variability. This can lead to increased availability of generics, fostering competition and reducing drug costs for consumers. The flexibility of SABE encourages pharmaceutical companies to develop generics for a broader range of drugs, including those previously deemed too variable to test effectively.

Future directions and innovations

The future of bioequivalence testing is likely to see further advancements building on the foundation of SABE. Continuous innovation in pharmacokinetic modelling, coupled with the integration of real-world evidence, could enhance the precision and applicability of bioequivalence assessments.

Moreover, the adoption of SABE could inspire the development of novel statistical methods and computational tools, making bioequivalence testing more efficient and accurate. The pharmaceutical industry and regulatory agencies will need to collaborate closely to ensure that these innovations are effectively integrated into the regulatory framework, maintaining a balance between flexibility and rigor.

CONCLUSION

Scaled average bioequivalence represents a significant evolution in the assessment of generic drugs, addressing the limitations of traditional methods when dealing with highly variable drugs. By incorporating the intrinsic variability of the reference drug into the bioequivalence criteria, SABE provides a more accurate and flexible framework for evaluating generics. This approach not only facilitates the approval of a broader range of generic drugs but also ensures that patients have access to affordable, high-quality medications. The adoption of SABE by major regulatory bodies underscores its importance in modern drug development. However, the successful implementation of SABE requires careful consideration of statistical methods, regulatory guidelines, and patient safety.

Correspondence to: Xinh Jon, Department of Chemistry, University of Sydney, Sydney, Australia, E-mail: xinj@gmail.com

Received: 17-May-2024, Manuscript No. JBB-24-26091; **Editor assigned:** 20-May-2024, PreQC No. JBB-24-26091 (PQ); **Reviewed**: 03-Jun-2024, QC No. JBB-24-26091; **Revised:** 10-Jun-2024, Manuscript No. JBB-24-26091 (R); **Published**: 17-Jun-2024, DOI: 10.35248/0975-0851.24.16.581.

Citation: Jon X (2024) Scaled Average Bioequivalency and Advancements in Generic Drug Development. J Bioequiv Availab. 16:581.